invasive fungal infection – Page 2

Detection and diagnostic process of liver abscess secondary to chemotherapy by mucor indicus in a patient with acute leukemic disease: case report

mycolabadmin

A 60-year-old man with acute leukemia developed a serious fungal infection in his liver caused by Mucor indicus after receiving chemotherapy that weakened his immune system. Doctors identified the infection through tissue samples and genetic testing, then treated him successfully with antifungal medications amphotericin B and posaconazole. This case highlights the importance of early detection and proper diagnosis of rare fungal infections in cancer patients undergoing chemotherapy.

Severe Saprochaete capitata fungemia presenting as micafungin breakthrough hepatosplenic lesions in an immunocompromised patient: case report

mycolabadmin

A 70-year-old woman with blood cancer developed a serious fungal blood infection caused by Saprochaete capitata, a rare soil fungus, despite taking preventive antifungal medication. The infection spread to her liver and spleen, creating multiple lesions and a dangerous aneurysm. Doctors successfully treated her with a combination of three antifungal drugs, particularly voriconazole, which proved more effective than the initial preventive medication. This case highlights how rare fungi can cause severe infections in cancer patients and the importance of recognizing when standard preventive treatments are not working.

Pulmonary Mucormycosis in Diabetic Patients: A Case Series From a Tertiary Respiratory Center in Sri Lanka

mycolabadmin

This case study describes three diabetic patients in Sri Lanka who developed a serious lung infection caused by a fungus called mucormycosis. The infection caused cavities in the lungs and symptoms like fever, cough, and weight loss. Two patients recovered with antifungal medication (amphotericin B) and surgery, while one patient sadly died despite receiving treatment. The study emphasizes that doctors should consider this infection in diabetic patients with unusual lung symptoms to catch it early.

Approaches to Invasive Fungal Diseases in Paediatric Cancer Centres: An Analysis of Current Practices and Challenges in Germany, Austria and Switzerland

mycolabadmin

This study examined how 62 children’s cancer hospitals in Germany, Austria and Switzerland manage fungal infections in young cancer patients. Researchers found that hospitals use different methods to prevent and treat these serious infections, with some having special fungal infection experts and others not. The study revealed that larger hospitals tend to have better resources and expertise, while smaller hospitals face challenges like drug interactions and delays in getting test results.

Magnusiomyces capitatus bloodstream infection in a patient with acute monocytic leukemia: A rare case report

mycolabadmin

A 26-year-old patient with acute leukemia developed a serious fungal blood infection caused by Magnusiomyces capitatus, a rare organism found in environmental sources. The infection was confirmed using advanced molecular techniques and showed resistance to common antifungal drugs but responded to amphotericin B treatment. This case highlights how important it is for doctors to consider unusual fungi in severely immunocompromised patients and to use modern diagnostic methods for accurate identification and tailored treatment.

The Impact of the Fungal Priority Pathogens List on Medical Mycology: A Northern European Perspective

mycolabadmin

Fungal infections affect over a billion people worldwide but are often overlooked in healthcare. The World Health Organization recently created a priority list of dangerous fungi to help doctors and researchers focus their efforts. This review discusses how this list can improve diagnosis, testing, and treatment of fungal infections across Europe, while also highlighting the need for better training and awareness among healthcare workers.

Cryptococcus: Emerging host risk factors for infection

mycolabadmin

This scientific review examines why some people without HIV are getting serious Cryptococcus infections and becoming very sick. Researchers found that people with liver problems, kidney disease, diabetes, cancer, and autoimmune diseases face much higher risk. The review also identifies new drugs and therapies that can surprisingly increase infection risk, highlighting the importance of understanding individual patient factors when treating these dangerous fungal infections.

Epidemiology of mucormycosis in COVID-19 patients in northwest Iran: Rhizopus arrhizus as the predominant species

mycolabadmin

During the COVID-19 pandemic, a dangerous fungal infection called mucormycosis was found in 63 patients in northwestern Iran. The infection was caused mainly by a fungus called Rhizopus arrhizus and most commonly affected the sinuses and brain. Most patients had been given high-dose steroids to treat their COVID-19, which weakened their immune systems and increased their risk of this serious fungal infection, especially those with diabetes.

ESCMID-EFISG Survey on Diagnostic and Therapeutic Capacity for Invasive Fungal Infections in Belgium, the Netherlands, and Luxembourg: A Focus on High Azole Resistance

mycolabadmin

This survey examined how well hospitals in Belgium, the Netherlands, and Luxembourg can diagnose and treat serious fungal infections, which are particularly dangerous for people with weakened immune systems. The researchers found that while most hospitals can test fungal samples, not all have access to all necessary diagnostic tools, especially tests for detecting resistant fungi and identifying fungal co-infections. Many hospitals outsource their testing to other facilities, which can delay diagnosis and treatment, and some hospitals lack access to all recommended antifungal medications.

Antifungal Effects of the Phloroglucinol Derivative DPPG Against Pathogenic Aspergillus fumigatus

mycolabadmin

Scientists developed a new antifungal compound called DPPG based on a natural antibacterial molecule produced by soil bacteria. This synthetic derivative showed strong activity against dangerous fungal pathogens like Aspergillus fumigatus and Candida species, which cause serious infections in humans. The compound works by disrupting the fungal cell membrane, causing it to leak and die. Testing in insect models demonstrated effectiveness comparable to current clinical antifungal medications.

Research Keyword: invasive fungal infection